資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/36356
|
| 題名: | 綠藻對 L-NAME 誘發高血壓大鼠血壓和組織損傷之影響
Effects of Chlorella on Blood Pressure and Cardiorenal Remodeling in L-NAME-Induced Hypertensive Rats |
| 作者: | 楊宜靜
Yang Yi-Ching |
| 貢獻者: | 保健營養學研究所
陳俊榮 |
| 關鍵詞: | 碩士
指導教授-陳俊榮
委員-王銘富
委員-楊欣怡
綠藻;高血壓;血管收縮素轉換酶;一氧化氮
Chlorella;hypertension;angiotensin-converting enzyme;nitric oxide |
| 日期: | 2010 |
| 上傳時間: | 2010-10-20 12:14:28 (UTC+8) |
| 摘要: | 高血壓為造成心血管疾病的主要危險因子之ㄧ。綠藻含有豐富的蛋白質，且有體外實驗指出綠藻蛋白的水解物具有抑制血管收縮素轉換酶(angiotensin- converting enzyme, ACE) 的活性。本研究探討在投予實驗動物一氧化氮合成酶抑制劑 Nω-nitro-l-arginine methyl ester hydrochloride (L-NAME) 來模擬內皮功能不良高血壓的動物模式中，飲食中添加綠藻是否能藉由調節氧化壓力、發炎反應、增加 NO 前驅物 - L-arginine 與抑制 ACE 活性的作用來改善血壓上升與組織損傷。組別分為控制組 (C)、L-NAME組 (L)、L-NAME + 4% 綠藻組 (G1)、L-NAME + 8% 綠藻組 (G2)，進行為期五週的實驗。實驗結果發現：攝取綠藻的組別收縮壓和舒張壓皆顯著低於 L 組 (P < 0.05)、且攝取綠藻的實驗動物血漿中 PAI-1 濃度、血液與組織中的 ACE 活性、組織中 TNF-?? 濃度及腎臟 CYP4A 表現量也都顯著低於 L 組 (P < 0.05)，但在 MDA、NOx 及 arginine 的濃度與 L 組相較則無顯著差異。在病理組織切片中，同樣也觀察到攝取綠藻可改善實驗動物心臟和腎臟組織損傷的情形。由以上結果推論：在內皮損傷的大鼠模式中，攝取綠藻可能有助於延緩一氧化氮缺乏所造成的血壓上升和心血管、腎臟組織的發炎及損傷，且其中可能的機制之ㄧ是藉由抑制血液和組織中的ACE活性。
Hypertension is one of the main factors causing cardiovascular disease. In vitro study has reported that some ACE-inhibitory peptides may be produced by enzymatic digestion of chlorella. In the present study, we investigated the effects of chlorella on blood pressure and cardiorenal remodeling in rats with Nω-nitro-l-arginine methyl ester hydrochloride (L-NAME)-induced hypertension. Rats were fed a diet containing L-NAME (40 mg/kg body weight) with or without chlorella (4% or 8%) for 5 weeks. We found that chlorella retarded the development of hypertension and cardiorenal remodeling during the 5-week experimental period. Although there was no difference in MDA, NOx levels and plasma arginine concentrations, plasma and tissues ACE activities were significantly lower in chlorella groups than in the L-NAME group (P < 0.05). Moreover, tissue tumor necrosis factor-α concentrations and renal CYP4A expression were also lower in the chlorella groups (P < 0.05). These results suggest that chlorella might ameliorate the elevation of blood pressure and show cardiorenal-protective effects in nitric oxide (NO)-deficient rats, and one possible mechanism might be mediated via its ACE inhibitory activity. |
| 關聯: | 70頁 |
| 描述: | 目錄
摘要 I
Abstract II
致謝 III
目錄 V
表目錄 VII
圖目錄 VIII
前言 1
第一章 文獻回顧 3
(一) 高血壓 3
(二) 高血壓與腎素血管收縮素系統 5
(三) 高血壓與內皮功能 7
(四) 內皮功能的損傷與治療 9
(五) 綠藻簡介 12
(六) 綠藻對氧化壓力與發炎反應的影響 13
(七) 綠藻對血壓的影響 14
第二章 研究目的 16
第三章 研究方法 17
(一) 實驗動物 17
(二) 實驗設計 17
(三) 分析項目 18
(四) 統計分析 24
第四章 結果 25
(一) 體重、攝食量與飲水量 25
(二) 血液基本生化值 25
(三) 尿液分析 26
(四) 血壓 26
(五) 脂質過氧化物濃度 26
(六) 血漿胺基酸分析與 NO 濃度 27
(七) ACE 活性 27
(八) TNF-?? 與 PAI-1 濃度 28
(九) 組織病理切片 28
(十) 腎臟中 CYP4A 的表現量 29
第五章 討論 30
(一) 血液基本生化值 30
(二) 綠藻對血壓的影響 31
(三) 綠藻對氧化壓力的影響 32
(四) 綠藻對 L-arginine 與 NO 的影響 35
(五) 綠藻對ACE 活性的影響 38
(六) 綠藻對組織損傷與發炎、纖維化的影響 40
第六章 結論 43
參考文獻 44
Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR and Roman RJ (1997) Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29: 320-5
Anderson S and Brenner BM (1986) The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens Suppl 4: S236-8
Arcos MI, Fujihara CK, Sesso A, de Almeida Prado EB, de Almeida Prado MJ, de Nucci G and Zatz R (2000) Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol 279: F1060-6
Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H and Chmara E (2010) Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit 16: CR266-71
Bachmann S and Mundel P (1994) Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis 24: 112-29
Bautista LE, Vera LM, Arenas IA and Gamarra G (2005) Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 19: 149-54
Baylis C, Mitruka B and Deng A (1992) Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-81
Bernatova I, Pechanova O and Simko F (1999) Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 84: 1095-105
Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J and Prager GW (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17: 56-61
Bouchie JL HH, Feener EP (1998) Natriuretic factor and nitric oxide supress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 18: 1771-1779
Castillo L, Beaumier L, Ajami AM and Young VR (1996) Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. Proc Natl Acad Sci U S A 93: 11460-5
Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D and Ferrari R (2007) ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 73: 237-46
Chen X, Touyz RM, Park JB and Schiffrin EL (2001) Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38: 606-11
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr. and Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-72
De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE and Rossoni G (2005) Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol 516: 253-9
de Nigris F, Lerman A, Ignarro LJ, Williams-Ignarro S, Sica V, Baker AH, Lerman LO, Geng YJ and Napoli C (2003) Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends Mol Med 9: 351-9
Fogari R and Zoppi A (2005) Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant? Am J Cardiovasc Drugs 5: 211-23
Fyhrquist F and Saijonmaa O (2008) Renin-angiotensin system revisited. J Intern Med 264: 224-36
Garcia-Estan J, Ortiz MC, O'Valle F, Alcaraz A, Navarro EG, Vargas F, Evangelista S and Atucha NM (2006) Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Clin Sci (Lond) 110: 227-33
Gewaltig MT and Kojda G (2002) Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55: 250-60
Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G and Cooper ME (1998) Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47: 414-22
Gokce N (2004) L-arginine and hypertension. J Nutr 134: 2807S-2811S; discussion 2818S-2819S
Gonzalez W, Fontaine V, Pueyo ME, Laquay N, Messika-Zeitoun D, Philippe M, Arnal JF, Jacob MP and Michel JB (2000) Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 36: 103-9
Griesmacher A, Kindhauser M, Andert SE, Schreiner W, Toma C, Knoebl P, Pietschmann P, Prager R, Schnack C, Schernthaner G and et al. (1995) Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 98: 469-75
Guzman S, Gato A and Calleja JM (2001) Antiinflammatory, analgesic and free radical scavenging activities of the marine microalgae Chlorella stigmatophora and Phaeodactylum tricornutum. Phytother Res 15: 224-30
Hanada T and Yoshimura A (2002) Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13: 413-21
Harrison DG (1997) Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-7
Holmquist B, Bunning P and Riordan JF (1979) A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 95: 540-8
Huang H, Zhou Y, Raju VT, Du J, Chang HH, Wang CY, Brands MW, Falck JR and Wang MH (2005) Renal 20-HETE inhibition attenuates changes in renal hemodynamics induced by L-NAME treatment in pregnant rats. Am J Physiol Renal Physiol 289: F1116-22
Ignarro LJ, Cirino G, Casini A and Napoli C (1999) Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34: 879-86
Imig J D ZA, Stec DE, Harder DR, Falck JR, Roman RJ (1996). Formation and action of 20-HETE on renal arterioles. Am J Physiol. 270: R217-R227.
Ito O, Omata K, Ito S, Hoagland KM and Roman RJ (2001) Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid. Am J Physiol Regul Integr Comp Physiol 280: R822-30
Ito S (1995) Nitric oxide in the kidney. Curr Opin Nephrol Hypertens 4: 23-30
Jepson RE, Syme HM, Vallance C and Elliott J (2008) Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. J Vet Intern Med 22: 317-24
Jitsukawa K, Suizu R and Hidano A (1984) Chlorella photosensitization. New phytophotodermatosis. Int J Dermatol 23: 263-8
Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ and Vaughan DE (2001) Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104: 839-44
Kannel WB (2000) Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 14: 83-90
Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A and Narita H (2000) Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 32: 73-83
Kawada N, Imai E, Karber A, Welch WJ and Wilcox CS (2002) A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol 13: 2860-8
Kendler BS (2006) Supplemental conditionally essential nutrients in cardiovascular disease therapy. J Cardiovasc Nurs 21: 9-16
Khattab MM, Mostafa A and Al-Shabanah O (2005) Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. Kidney Blood Press Res 28: 243-50
Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M and Takeshita A (2000) Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 18: 1795-800
Kone BC and Baylis C (1997) Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 272: F561-78
Lee HS, Choi CY, Cho C and Song Y (2003) Attenuating effect of chlorella supplementation on oxidative stress and NFkappaB activation in peritoneal macrophages and liver of C57BL/6 mice fed on an atherogenic diet. Biosci Biotechnol Biochem 67: 2083-90
Leibowitz D, Planer D, Ben-Ivgi F, Weiss AT and Bursztyn M (2005) Tumor necrosis factor and interleukin-6 levels in hypertensive patients with and without left ventricular hypertrophy. Blood Press 14: 21-4
Leonetti G and Cuspidi C (1995) Choosing the right ACE inhibitor. A guide to selection. Drugs 49: 516-35
Lewington S, Clarke R, Qizilbash N, Peto R and Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-13
Lip GY and Blann AD (2008) Endothelium and fibrinolysis in hypertension: important facets of a prothrombotic state? Hypertension 52: 218-9
Luvarà G PM, Philippe M, Mandet C, Savoie F, Henrion D, Michel JB (1998) Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 18: 1408-16
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A and Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765-74
Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G and Bellomo G (1995) Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens 13: 129-38
Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ and Pitt B (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94: 258-65
Mann GE, Yudilevich DL and Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183-252
Mehta S, Stewart DJ and Levy RD (1996) The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 109: 1550-5
Merchant RE, Andre CA and Sica DA (2002) Nutritional supplementation with Chlorella pyrenoidosa for mild to moderate hypertension. J Med Food 5: 141-52
Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O and Vazquez CM (2008) The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 21: 1231-7
Miguel Carrasco JL, Zambrano S, Blanca AJ, Mate A and Vazquez CM (2010) Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kappaB. J Inflamm (Lond) 7: 21
Miranda KM, Espey MG and Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71
Miranda MS, Sato S and Mancini-Filho J (2001) Antioxidant activity of the microalga Chlorella vulgaris cultered on special conditions. Boll Chim Farm 140: 165-8
Mombouli JV (1997) ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs 54 Suppl 5: 12-22
Moss MB, Brunini TM, Soares De Moura R, Novaes Malagris LE, Roberts NB, Ellory JC, Mann GE and Mendes Ribeiro AC (2004) Diminished L-arginine bioavailability in hypertension. Clin Sci (Lond) 107: 391-7
Murray BA and FitzGerald RJ (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 13: 773-91
Nakamura S, Nakamura I, Ma L, Vaughan DE and Fogo AB (2000) Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58: 251-9
Namsa ND, Tag H, Mandal M, Kalita P and Das AK (2009) An ethnobotanical study of traditional anti-inflammatory plants used by the Lohit community of Arunachal Pradesh, India. J Ethnopharmacol 125: 234-45
Napoli C, de Nigris F and Palinski W (2001) Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 82: 674-82
Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ and Liguori A (2004) Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 148: e5
Negro R (2008) Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 4: 89-101
Okamoto K, Iizuka Y, Murakami T, Miyake H and Suzuki T (1978) Effects of chlorella alkali extract on blood pressure in SHR. Jpn Heart J 19: 622-3
Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T and Miyazaki M (1991) Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 18: 649-59
Oyekan AO, Youseff T, Fulton D, Quilley J and McGiff JC (1999) Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 104: 1131-7
Palumbo G, Avanzini F, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, Capra A, Rossi S, Nosotti L, Costantini C and Cavalera C (2000) Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study. Am J Hypertens 13: 564-7
Park JY, Cho HY, Kim JK, Noh KH, Yang JR, Ahn JM, Lee MO and Song YS (2005) Chlorella dichloromethane extract ameliorates NO production and iNOS expression through the down-regulation of NF kappa B activity mediated by suppressed oxidative stress in RAW 264.7 macrophages. Clin Chim Acta 351: 185-96
Paterna S, Di Garbo V, Avellone G, Di Pasquale P, Cacia A, Tuttolomondo A, Follone G, Cardinale A, Maniscalchi T and Licata G (2003) Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension. Clin Drug Investig 23: 717-24
Patzak A and Persson AE (2007) Angiotensin II-nitric oxide interaction in the kidney. Curr Opin Nephrol Hypertens 16: 46-51
Paul M, Poyan Mehr A and Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803
Pechanova O and Simko F (2009) Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 27 Suppl 6: S32-6
Pereira LM, Almeida JR and Mandarim-de-Lacerda CA (2004) Kidney adaptation in nitric oxide-deficient Wistar and spontaneously hypertensive rats. Life Sci 74: 1375-86
Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G and Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46: 518-23
Rauchova H, Pechanova O, Kunes J, Vokurkova M, Dobesova Z and Zicha J (2005) Chronic N-acetylcysteine administration prevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species. Hypertens Res 28: 475-82
Rees DD, Palmer RM, Schulz R, Hodson HF and Moncada S (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-52
Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM and Zatz R (1992) Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303
Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G and Egido J (2006) Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 15: 159-66
Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M and Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-9
Sansawa H, Takahashi M, Tsuchikura S and Endo H (2006) Effect of chlorella and its fractions on blood pressure, cerebral stroke lesions, and life-span in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 52: 457-66
Schiffrin EL (2004) Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 17: 1192-200
Shalaby SM, Zakora M and Otte J (2006) Performance of two commonly used angiotensin-converting enzyme inhibition assays using FA-PGG and HHL as substrates. J Dairy Res 73: 178-86
Shibata S, Oda K, Onodera-Masuoka N, Matsubara S, Kikuchi-Hayakawa H, Ishikawa F, Iwabuchi A and Sansawa H (2001) Hypocholesterolemic effect of indigestible fraction of Chlorella regularis in cholesterol-fed rats. J Nutr Sci Vitaminol (Tokyo) 47: 373-7
Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F and Strazzullo P (2000) Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens 13: 547-51
Sprague AH and Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol
Suetsuna K and Chen JR (2001) Identification of antihypertensive peptides from peptic digest of two microalgae, Chlorella vulgaris and Spirulina platensis. Mar Biotechnol (NY) 3: 305-9
Susic D (2000) Renal protective potential of antihypertensive drugs. Expert Opin Investig Drugs 9: 2593-600
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V and Egido J (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900
Taddei S, Virdis A, Ghiadoni L, Magagna A, Pasini AF, Garbin U, Cominacini L and Salvetti A (2001) Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 19: 1379-86
Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I and Salvetti A (1996) Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94: 1298-303
Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K and Takeshita A (1997) Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99: 278-87
Todd PA and Heel RC (1986) Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198-248
Tomohiro A, Kimura S, He H, Fujisawa Y, Nishiyama A, Kiyomoto K, Aki Y, Tamaki T and Abe Y (1997) Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-arginine supplementation. Am J Physiol 272: R1013-9
Treasure CB KJ, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J (1995) Beneficial effects of cholesterol-lowing therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487
Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB and Levy D (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291-7
Vassalli JD, Sappino AP and Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-72
Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M and Badimon L (2005) Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens 19: 457-62
Vidt DG, Bravo EL and Fouad FM (1982) Medical intelligence drug therapy: captopril. N Engl J Med 306: 214-9
Vijan SG (2009) Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J Indian Med Assoc 107: 178-82
Vijayavel K, Anbuselvam C and Balasubramanian MP (2007) Antioxidant effect of the marine algae Chlorella vulgaris against naphthalene-induced oxidative stress in the albino rats. Mol Cell Biochem 303: 39-44
Whitworth JA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983-92
Yasukawa K, Akihisa T, Kanno H, Kaminaga T, Izumida M, Sakoh T, Tamura T and Takido M (1996) Inhibitory effects of sterols isolated from Chlorella vulgaris on 12-0-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin. Biol Pharm Bull 19: 573-6
Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC and Zhang C (2009) Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 116: 219-30
Zhou MS, Schulman IH and Raij L (2004) Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 24: 366-78 |
| 資料類型: | thesis |
| 顯示於類別: | [保健營養學系暨研究所] 碩博士論文
|
文件中的檔案:
| 檔案 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | 0Kb | HTML | 136 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
